BILLERICA, Mass.--(BUSINESS WIRE)--Millipore Corporation (NYSE:MIL) today announced that it has entered into a worldwide, non-exclusive license agreement with Bayer HealthCare AG, a subsidiary of Bayer AG, to use Millipore’s UCOE™ (Ubiquitous Chromatin Opening Element) technology to manufacture its biologic drugs. The license will enable Bayer to more efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations. Financial terms were not disclosed.
